Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Steatosis of Liver Clear all
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT02781584
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
SEL, FIR, CILO, FENO, VAS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Chandler, Arizona • La Jolla, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Jul 23, 2026, 1:41 AM EDT
Completed Not applicable Interventional

Dietary Interventions in Prediabetes

NCT01729078
View directory record Official record
Conditions
Impaired Fasting Glucose, Pre Diabetes, Liver Fat
Interventions
Dietary intervention
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Jul 23, 2026, 1:41 AM EDT
Recruiting Not applicable Interventional

Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD

NCT07192159
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
Interventions
Quantitative ultrasound (DeepUSFF)
Device
Lead sponsor
Seoul National University Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT01694849
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
GFT505 80mg, GFT505 120mg, Placebo
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Fresno, California • La Jolla, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Jul 23, 2026, 1:41 AM EDT
Recruiting Not applicable Interventional

Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

NCT07646197
View directory record Official record
Conditions
MASLD, Fatty Liver
Interventions
Peanut consumption
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
30 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 23, 2026, 1:41 AM EDT
Terminated Phase 2 Interventional

Total Parenteral Nutrition-Associated Liver Disease

NCT00031135
View directory record Official record
Conditions
Liver Diseases
Interventions
Choline Chloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 74 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 23, 2026, 1:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis

NCT04669158
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis, Fibrosis
Interventions
Idebenone, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Redwood City, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alpelisib in Healthy Volunteers

NCT05733455
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Dyslipidemias
Interventions
Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage, BOOST Plus nutritional beverage
Drug · Device · Diagnostic Test + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jul 23, 2026, 1:41 AM EDT
Recruiting No phase listed Observational

Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)

NCT04634643
View directory record Official record
Conditions
NAFLD
Interventions
Usual diet and physical activity
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 18 Years
Enrollment
260 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jul 23, 2026, 1:41 AM EDT
Recruiting Phase 3 Interventional

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatohepatitis
Interventions
Survodutide, Placebo matching survodutide
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
125
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 1:41 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

NCT07221188
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin Alfa, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
43
States / cities
Arcadia, California • Covina, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 23, 2026, 1:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)

NCT00994682
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Pioglitazone study drug, Placebo, Pioglitazone Open Label
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT02854605
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
GS-9674, Placebo to match GS-9674
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Los Angeles, California • Rialto, California • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Jul 23, 2026, 1:41 AM EDT
Completed No phase listed Observational

Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

NCT00326482
View directory record Official record
Conditions
Liver Fibrosis, Steatohepatitis, Elevated Transaminases
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

NCT04091061
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
PF-06865571 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Jul 23, 2026, 1:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Metabolic Pathology of Pediatric NAFLD

NCT05430178
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
Interventions
Oral sugar tolerance test, De novo lipogenesis test, Gluconeogenesis test
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
10 Years to 20 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jul 23, 2026, 1:41 AM EDT
Recruiting No phase listed Observational

Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database

NCT02897908
View directory record Official record
Conditions
Disease of Liver and Bile Duct
Interventions
vibration controlled transient elastography (VCTE)
Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 1:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Liver in the World Trade Center Health Program General Responder Cohort and Controls

NCT03858920
View directory record Official record
Conditions
Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
Fibroscan of Liver, Low-dose non-contrast CT
Device · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Jul 23, 2026, 1:41 AM EDT
Completed No phase listed Observational

Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery

NCT01007955
View directory record Official record
Conditions
Morbid Obesity, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Jul 23, 2026, 1:41 AM EDT
Terminated Phase 4 Interventional Results available

Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT00736385
View directory record Official record
Conditions
Fatty Liver
Interventions
Glucophage (Metformin), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Jul 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

NCT03517540
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor (LJN452), Cenicriviroc (CVC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jul 23, 2026, 1:41 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

NCT06176079
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Interventions
Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush
Drug · Procedure
Lead sponsor
Michael Ohliger, MD PhD
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Jul 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

NCT05553470
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Miricorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Rialto, California • Miami, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Jul 23, 2026, 1:41 AM EDT
Not listed No phase listed Observational

Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US

NCT06051669
View directory record Official record
Conditions
Liver Fibrosis, Fatty Liver
Interventions
iLivTouch, FibroScan
Device
Lead sponsor
New Discovery LLC
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Redwood City, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 23, 2026, 1:41 AM EDT